The objective of the TOP trial is to determine whether higher hemoglobin thresholds for transfusing ELBW infants resulting in higher hemoglobin levels lead to improvement in the primary outcome of survival and rates of neurodevelopmental impairment (NDI) at 22-26 months of age, using standardized assessments by Bayley.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Death or Neurodevelopmental Impairment
Timeframe: Birth to 22-26 months corrected age
Death
Timeframe: Birth to 22-26 months corrected age
Neurodevelopmental Impairment
Timeframe: at 22-26 months corrected age
Cognitive Delay
Timeframe: at 22-26 months corrected age
Moderate or Severe Cerebral Palsy
Timeframe: at 22-26 months corrected age
Severe Vision Impairment
Timeframe: at 22-26 months corrected age
Severe Hearing Impairment
Timeframe: at 22-26 months corrected age